Keywords: market, cox-2, inhibitors, poised, rapid, growth, record-breaking
Market for COX-2 inhibitors "poised for rapid growth"
Article | 04 March 2002
Since the record-breaking first-year sales of Pharmacia and Pfizer'sCelebrex (celecoxib) and Merck & Co's Vioxx (rofecoxib), the COX-2 inhibitors have emerged ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
